Regular Article

British Journal of Cancer (1999) 79, 1168–1173. doi:10.1038/sj.bjc.6690186 www.bjcancer.com
Published online 12 February 1999

Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma

S Uchida1, Y Shimada1, G Watanabe1, Z Gang Li1, T Hong1, M Miyake2 and M Imamura1

  1. 1Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, 54-Syogoin kawara-cho, Sakyoku, Kyoto 606-8507, Japan
  2. 2Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka 530, Japan

Received 23 October 1997; Revised 9 March 1998; Accepted 30 June 1998.

Top

Abstract

Although the mechanisms of action of the transmembrane superfamilies, motility-related protein-1 (MRP-1/CD9) and KAI1/CD82, are not well known, they are reported to suppress the metastasis of several kinds of cancers. The suppression of cell motility by MRP-1/CD9 may cause suppression of the metastasis. As we could not find any reports concerning the expression of MRP-1/CD9 and KAI1/CD82 in oesophageal cancers we investigated their expression in oesophageal specimens. We conducted immunohistochemical staining for MRP-1/CD9 against 108 cases of oesophageal squamous cell carcinoma using anti-MRP-1/CD9 monoclonal antibody M31-15, and for KAI1/CD82 against 104 cases using anti-KAI1/CD82 monoclonal antibody C33. To investigate the gradual expression of MRP-1/CD9 and KAI1/CD82, 24 oesophageal dysplasias were immunohistochemically stained using the same method and then investigated.

The expression of both MRP-1/CD9 and KAI1/CD82 were positive on the cell membranes of normal oesophageal epithelial cells, but reduced or negative in the cancer cells. Reduced MRP-1/CD9 expressions significantly correlated to tumour depth (P = 0.0009). We found a significantly greater number of reduced or negative expression of MRP-1/CD9 and KAI1/CD82 in lymph node metastatic cases (P = 0.0003 and P = 0.0129, respectively), but not in distant metastatic cases. The 5-year survival rate of MRP-1/CD9-negative and reduced patients was significantly worse than those of positive patients (n = 108, curative cases, RO). Few cases remained KAI1/CD82-positive (9.6%; 10/104) in oesophageal cancer. Twenty (83.3%) and twenty-two (91.7%) cases out of 24 dysplasias were defined as KAI1/CD82-positive and MRP-1/CD9-positive, respectively. The decrease in MRP-1/CD9 and KAI1/CD82 expression may facilitate lymph node metastasis in oesophageal squamous cell carcinomas. Knowing the status of the expression of MRP-1/CD9 appears helpful in predicting the prognosis for each patient.

Keywords:

oesophageal carcinoma, MRP-1/CD9, KAI1/CD82

Top

References

  1. Adachi, M., Taki, T., Ieki, Y., Huang, C. L., Higashiyama, M. & Miyake, M. (1996). Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res, 56: 1751–1755. | PubMed | ISI | ChemPort |
  2. Boucheix, C., Benoit, P., Frachet, P., Billard, M., Worthington, R. E., Gagnon, J. & Uzan, G. (1991). Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem, 266: 117–122. | PubMed |
  3. Cajot, J. F., Sordat, I., Silvestre, T. & Sordat, B. (1997). Differential display cloning identifies motility-related protein (MRP-1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res, 57: 2593–2597. | PubMed | ISI | ChemPort |
  4. Dong, J. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Issac, J. T. & Barrett, J. C. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science, 268: 884–886. | Article | PubMed | ISI | ChemPort |
  5. Dong, J. T., Suzuki, H., Pin, S. S., Bova, G. S., Schalken, J. A., Issacs, W. B., Barrett, J. C. & Issacs, J. T. (1996). Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res, 56: 4387–4390. | PubMed | ISI | ChemPort |
  6. Hakomori, S. (1989). Aberrant glycolation in tumors and tumor-associated carbohydrate antigen. In Advances in Cancer Research, Vande-Woude GF, Klein G (eds), pp. 257–331, Academic Press: San Diego
  7. Hato, T., Ikeda, K., Yasukawa, M., Watanabe, A. & Kobayashi, Y. (1988). Exposure of platelet fibrinogen receptors by a monoclonal antibody to CD9 antigen. Blood, 72: 224–229.
  8. Hermanek, P. & Sobin, L. H. (1987). TNM classification of malignant tumours, 4th edn, pp 40–42, Springer Verlag: Berlin
  9. Higashihara, M., Takahata, K., Yatomi, Y., Nakahara, K. & Kurokawa, K. (1990). Purification and partial characterization of CD9 antigen of human platelets. FEBS, 264: 270–274.
  10. Higashiyama, M., Taki, T., Ieki, Y., Adachi, M., Huang, C. L., Koh, T., Kodama, K., Doi, O. & Miyake, M. (1995). Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res, 55: 6040–6044. | PubMed | ISI | ChemPort |
  11. Higashiyama, S., Iwamoto, R., Goishi, K., Raab, G., Taniguchi, N., Klagsbrun, M. & Mekada, E. (1995). The membrane protein CD9/DRAP 27 potentiates the jutacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol, 128: 929–938. | Article | PubMed | ISI | ChemPort |
  12. Ikeyama, S., Koyama, M., Yamaoko, M., Sasada, R. & Miyake, M. (1993). Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med, 177: 1231–1237. | Article | PubMed | ISI | ChemPort |
  13. Imamura, M., Ohishi, K., Mizutani, N., Yanagibashi, K., Naito, M., Shimada, Y., Hattori, Y., Satomura, K. & Tobe, T. (1987). Retrosternal esophagogastrostomy with EEA stapler after subtotal resection of the esophagus: application and results. Dig Surg, 4: 101–105.
  14. Miyake, M., Koyama, M., Seno, M. & Ikeyama, S. (1991). Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med, 174: 1347–1354. | Article | PubMed | ISI | ChemPort |
  15. Miyake, M., Nakano, K., Ieki, Y., Adachi, M., Huang, C. L., Itoi, S., Koh, T. & Taki, T. (1995). Motility-related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res, 55: 4127–4131. | PubMed | ISI | ChemPort |
  16. Nakamura, K., Iwamoto, R. & Mekada, E. (1995). Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP 27)/CD9 form a complex with integrin alpha3beta1 at cell–cell contact sites. J Cell Biol, 129: 1691–1705. | Article | PubMed | ISI | ChemPort |
  17. Ueda, T., Ichikawa, T., Tamaru, J., Mikata, A., Akakura, K., Akimoto, S., Imai, T., Yoshie, O., Shiraishi, T., Yatani, R., Ito, H. & Shimazaki, J. (1996). Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol, 149: 1435–1440. | PubMed |